In vitro cytotoxic study (IC50 values μM) of the target compounds 18c, 18g, and 18h against three cancer cell lines and WI38 normal cell line.
| Compd no. | Mean GI% | In vitro cytotoxicitya IC50 (μM) | Mean tumor selectivity indexb | ||||
|---|---|---|---|---|---|---|---|
| Leukemia | Breast cancer | HL-60 | MCF-7 | MDA-MB-231 | WI38 | ||
| 18c | 35 | 16 | 8.43 ± 1.7 | 16.2 ± 0.72 | 12.54 ± 0.56 | 34.81 ± 1.54 | 3.02 |
| 18g | 63 | 31 | 10.43 ± 0.68 | 11.7 ± 0.96 | 4.07 ± 0.18 | 26.19 ± 1.16 | 3.73 |
| 18h | 46 | 24 | 8.99 ± 0.4 | 12.48 ± 0.55 | 7.18 ± 0.32 | 40.9 ± 1.81 | 4.51 |
| Afatinib | — | — | 6.50 ± 0.77 | 7.91 ± 0.66 | 8.05 ± 0.72 | 44.01 ± 1.9 | 5.93 |
| Staurosporine | — | — | 5.191 ± 0.23 | 3.841 ± 0.17 | 5.814 ± 0.26 | 20.23 ± 0.9 | 4.21 |
| DOX | — | — | 6.01 ± 0.2 | 4.77 ± 0.4 | 5.10 ± 0.31 | 7.12 ± 0.7 | 1.36 |
a
IC50 value is the concentration of compound that inhibits 50% of the cancer cell growth after 48 h of drug exposure, as obtained from the MTT assay. Each value was shown as mean ± SD of three experiments.
b
Mean GI% and tumor selectivity index (WI38/HL60, MCF7, and MDA-MB-231).